U.S. drug regulators on Feb. 11 announced they are pushing back a decision on Pfizer’s COVID-19 vaccine for children as young as 6 months old. The Food and Drug Administration (FDA) had planned to consult its vaccine advisory committee on Feb. 15 on whether to clear the jab for young children, but changed that plan…
FDA Postpones Decision on Pfizer COVID-19 Vaccine for Young Children
Japan Grants Fast-Track Approval for Pfizer’s Oral COVID-19 Drug
Japan’s Health Ministry on Thursday granted fast-track approval for Pfizer’s oral COVID-19 drug, Paxlovid, to treat patients with mild symptoms amid the rapid spread of the coronavirus fueled by the Omicron variant in the country. The ministry said in a statement that it has secured 2 million courses of treatment with the U.S.-based drugmaker Pfizer,…
Facts Matter (Feb. 9): Pfizer Quietly Adds Warning That ‘Unfavorable Pre-Clinical, Clinical, or Safety Data’ May Impact Business
As we get closer and closer to the day that the FDA has to release its first batch of 55,000 pages of clinical trial documents, it looks like Pfizer is bracing for impact. That’s because it was just revealed that Pfizer updated its fourth-quarter investor report—the section on potential risks to their business. Specifically, they…
Pfizer Forecasts $54 Billion in Sales This Year as Demand for COVID-19 Vaccine and Treatment Pill Continues
February 9, 2022
admin
Business & EconomyBusinesses in COVID-19CCP VirusCompaniesCOVID-19economyPfizerUSUS NewsVaccineVaccines & Safety
0 Comment
Pfizer on Tuesday said it expects to see continued demand for its products this year, forecasting $54 billion in combined sales of its COVID-19 vaccine shots and antiviral pills. The American pharmaceutical and biotechnology giant said it expects to sell $32 billion of its vaccinations and $22 billion of its antiviral COVID-19 treatment pill Paxlovid in…
Pfizer Reports Bumper Income from COVID-19 Vaccine Sales In 2021, But Forecasts for 2022 Disappoint
Pfizer’s COVID-19 vaccine brought in a bumper income of nearly $37 billion in sales for 2021, the product’s first full year on the market, though Pfizer’s revenue forecasts for 2022 came in below analysts’ expectations, sending its shares down by over 5 percent. Called Comirnaty, the company’s two-dose COVID-19 vaccine generated $36.78 billion in revenue…
Pfizer Reports Nearly 37 Billion in COVID-19 Vaccine Sales Last Year
Pfizer’s COVID-19 vaccine brought in a bumper income of nearly $37 billion in sales for 2021, the product’s first full year on the market, though Pfizer’s revenue forecasts for 2022 came in below analysts’ expectations, sending its shares down by over 5 percent. Called Comirnaty, the company’s two-dose COVID-19 vaccine generated $36.78 billion in revenue…
COVID-19 Vaccines “Overwhelmingly Favourable” Given Scarcity of Myocarditis: Report
February 7, 2022
admin
Australiaaustralian medical journalCCP VirusCOVID-19Moderna COVID-19 vaccinemyocarditisPfizerVaccines & SafetyWorld
0 Comment
A clinical study conducted by the Royal Melbourne Hospital of a 20 year old man exhibiting symptoms of myocarditis upon the second administration of a COVID-19 mRNA vaccine concluded that given the scarcity of myocarditis, COVID-19 mRNA vaccine are still “overwhelmingly favourable for all age and sex groups, including young people.” The research team, led…
Report Concludes COVID-19 Vaccine-Induced Myocarditis Remains Rare in Australia
February 7, 2022
admin
Australiaaustralian medical journalCCP VirusCOVID-19Moderna COVID-19 vaccinemyocarditisPfizerVaccines & SafetyWorld
0 Comment
The authors of a clinical study of a 20-year-old Australian man with symptoms of myocarditis that developed after his second dose of an mRNA COVID-19 vaccine have concluded that mRNA vaccines are still “overwhelmingly favourable for all age and sex groups, including young people.” The research team, led by Joshua Wong from the Royal Melbourne Hospital, examined…
Australian Research Declares mRNA Vaccines ‘Overwhelmingly Favourable’ Despite Causing Myocarditis
February 7, 2022
admin
Australiaaustralian medical journalCCP VirusCOVID-19Moderna COVID-19 vaccinemyocarditisPfizerVaccines & SafetyWorld
0 Comment
Australian researchers who studied a 20-year-old man with symptoms of myocarditis after his second Pfizer COVID-19 jab have argued that mRNA vaccines are still “overwhelmingly favourable” for all eligible age and sex groups. This is despite the country’s medicines regulator noting that myocarditis and pericarditis rates were increasing each week as vaccination rates rise. The…
Court Temporarily Blocks Pfizer’s Motion to Intervene in Vaccine Information Case
A federal judge on Feb. 7 denied, for now, an attempt from Pfizer to intervene in a case that has drawn international attention. U.S. District Judge Mark Pittman, a Trump nominee, said that Pfizer may be allowed to intervene in the future but not at this time. The case concerns documents on Pfizer’s COVID-19 vaccine…
-
Recent Posts
-
Archives
- May 2025
- April 2025
- July 2023
- June 2023
- May 2023
- April 2023
- March 2023
- February 2023
- January 2023
- December 2022
- November 2022
- October 2022
- September 2022
- August 2022
- July 2022
- June 2022
- May 2022
- April 2022
- March 2022
- February 2022
- January 2022
- December 2021
- November 2021
- October 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- September 2013
- July 2013
- March 2013
- January 2013
- December 2012
- November 2012
- December 1
-
Meta